Summary
Global Markets Direct’s, ‘Aspergillosis - Pipeline Review, H1 2016’, provides an overview of the Aspergillosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Aspergillosis
- The report reviews pipeline therapeutics for Aspergillosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Aspergillosis therapeutics and enlists all their major and minor projects
- The report assesses Aspergillosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Aspergillosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Aspergillosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amplyx Pharmaceuticals, Inc.
Astellas Pharma Inc.
Biomar Microbial Technologies
Cidara Therapeutics, Inc.
F2G Ltd
Hsiri Therapeutics, LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings, Inc.
Merck & Co., Inc.
Nanomerics Ltd
Novabiotics Limited
Pulmatrix, Inc.
Pulmocide Ltd
Scynexis, Inc.
Sealife PHARMA GMBH
Sigma-Tau S.p.A.
TGV-Laboratories
Vical Incorporated
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Aspergillosis Overview 10
Therapeutics Development 11
Pipeline Products for Aspergillosis - Overview 11
Pipeline Products for Aspergillosis - Comparative Analysis 12
Aspergillosis - Therapeutics under Development by Companies 13
Aspergillosis - Therapeutics under Investigation by Universities/Institutes 15
Aspergillosis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Aspergillosis - Products under Development by Companies 20
Aspergillosis - Products under Investigation by Universities/Institutes 21
Aspergillosis - Companies Involved in Therapeutics Development 22
Amplyx Pharmaceuticals, Inc. 22
Astellas Pharma Inc. 23
Biomar Microbial Technologies 24
Cidara Therapeutics, Inc. 25
F2G Ltd 26
Hsiri Therapeutics, LLC 27
iCo Therapeutics Inc. 28
Matinas BioPharma Holdings, Inc. 29
Merck & Co., Inc. 30
Nanomerics Ltd 31
Novabiotics Limited 32
Pulmatrix, Inc. 33
Pulmocide Ltd 34
Scynexis, Inc. 35
Sealife PHARMA GMBH 36
Sigma-Tau S.p.A. 37
TGV-Laboratories 38
Vical Incorporated 39
Aspergillosis - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
amphotericin B - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
amphotericin B - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
amphotericin B - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
amphotericin B - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
APX-001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ASP-9726 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Aspergillus fumigatus vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
C-001 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
C-016 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
F-901318 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
itraconazole - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
KB-425796C - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MDN-0018 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Myc-102 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
NP-339 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NP-525 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PC-945 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
posaconazole - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PTX-3 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SCY-078 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SLP-0901 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SLP-0904 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule for Aspergillosis - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules for Fungal Infections - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Fungal Infections - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules to Inhibit ABC Transporter for Fungal Infections - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
VL-2397 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Aspergillosis - Recent Pipeline Updates 80
Aspergillosis - Dormant Projects 87
Aspergillosis - Discontinued Products 89
Aspergillosis - Product Development Milestones 90
Featured News & Press Releases 90
Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis 90
Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397 90
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 91
Jan 06, 2016: FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis 91
Dec 17, 2015: Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA 92
Nov 30, 2015: F2G to Participate in the Adaptive Pathways Pilot Programme 93
Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015 93
Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397 94
Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate 95
Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas 95
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98
List of Tables
Number of Products under Development for Aspergillosis, H1 2016 11
Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Comparative Analysis by Unknown Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Investigation by Universities/Institutes, H1 2016 21
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 22
Aspergillosis - Pipeline by Astellas Pharma Inc., H1 2016 23
Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2016 24
Aspergillosis - Pipeline by Cidara Therapeutics, Inc., H1 2016 25
Aspergillosis - Pipeline by F2G Ltd, H1 2016 26
Aspergillosis - Pipeline by Hsiri Therapeutics, LLC, H1 2016 27
Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2016 28
Aspergillosis - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 29
Aspergillosis - Pipeline by Merck & Co., Inc., H1 2016 30
Aspergillosis - Pipeline by Nanomerics Ltd, H1 2016 31
Aspergillosis - Pipeline by Novabiotics Limited, H1 2016 32
Aspergillosis - Pipeline by Pulmatrix, Inc., H1 2016 33
Aspergillosis - Pipeline by Pulmocide Ltd, H1 2016 34
Aspergillosis - Pipeline by Scynexis, Inc., H1 2016 35
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2016 36
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H1 2016 37
Aspergillosis - Pipeline by TGV-Laboratories, H1 2016 38
Aspergillosis - Pipeline by Vical Incorporated, H1 2016 39
Assessment by Monotherapy Products, H1 2016 40
Number of Products by Stage and Target, H1 2016 42
Number of Products by Stage and Mechanism of Action, H1 2016 44
Number of Products by Stage and Route of Administration, H1 2016 46
Number of Products by Stage and Molecule Type, H1 2016 48
Aspergillosis Therapeutics - Recent Pipeline Updates, H1 2016 80
Aspergillosis - Dormant Projects, H1 2016 87
Aspergillosis - Dormant Projects (Contd..1), H1 2016 88
Aspergillosis - Discontinued Products, H1 2016 89
List of Figures
Number of Products under Development for Aspergillosis, H1 2016 11
Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 40
Number of Products by Targets, H1 2016 41
Number of Products by Stage and Targets, H1 2016 41
Number of Products by Mechanism of Actions, H1 2016 43
Number of Products by Stage and Mechanism of Actions, H1 2016 43
Number of Products by Routes of Administration, H1 2016 45
Number of Products by Stage and Routes of Administration, H1 2016 45
Number of Products by Molecule Types, H1 2016 47
Number of Products by Stage and Molecule Types, H1 2016 47
